Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
Pre-myeloma is a diagnostic term. This blog post is designed to outline the basics of the pre- myeloma aka pre-MM blood disorders of:
My experience as a cancer survivor and cancer coach is that the more someone understands about their diagnosis, the more in control they will feel, and the better their decision-making will be. The more in control you feel, the better your decision-making, the greater your quality and length of life.
Have you been given a diagnosis of pre-myeloma– a single plasmacytoma, MGUS or SMM? Are you experiencing any symptoms? Do you want to learn more about evidence-based, non-toxic therapies? Scroll down the page, post a comment or a question and I will reply to you ASAP.
The first thing that you must understand about a diagnosis of a single plasmacytoma, MGUS or SMM is that they are NOT cancer. Yes, these diagnoses increase your risks of a full myeloma diagnosis but they are blood disorders or pre-cancer stages.
The second thing that you should understand about your blood disorder is that you do not have to “watch and wait.”
You can reduce your risk of a myeloma diagnosis.
Yes, regular diagnostic testing to keep an eye on your monoclonal proteins is a good idea but there are steps you can take to reduce your risks of a full-blown diagnosis of multiple myeloma.
The third thing that I think pre-MM patients should understand is if their SPB. MGUS or SMM progresses to full-blown MM, they will be at an early stage of MM. Early stage or MM stage 1 is very different from the average newly diagnosed MM patient (NDMM).
According to research, 95% of NDMM patients are stage 2 or 3. Many present with bone or kidney involvement. The stage 1 MM NDMM patients is different and therefore has a much better (longer) prognosis.
In my experience, the standard-of-care treatment plan for the average NDMM patient much too much toxicity. In other words, induction chemotherapy, an autologous stem cell transplant both followed by low-dose maintenance therapy- all three are the SOC for NDMM, is a lot of chemo. A lot of toxicity.
It is up to the patient of course, but consider a treatment plan that is less toxicity, less chemotherapy.
To learn more about the evidence-based therapies you can follow to manage your pre-Myeloma and prevent full-blown Myeloma from developing, please watch the short video below:
Each area of interest below is linked to specific information for you to pursue if you choose to.
Consider Pre-Myeloma therapies such as:
Multiple Myeloma Complications
Multiple myeloma can cause problems including:
Smouldering myeloma is characterised by:
If you do not want to “watch and wait” to see if your MGUS progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP…”
“MGUS, is a condition in which a paraprotein is found in the blood during standard laboratory blood tests. It resembles multiple myeloma and similar diseases, but the levels of antibody are lower, the number of plasma cells (white blood cells that secrete antibodies) in the bone marrow is lower, it has no symptoms or major problems…”
MGUS is a common, age-related medical condition characterized by an accumulation of bone marrow plasma cells derived from a single abnormal clone. Patients may be diagnosed with MGUS if they fulfill the following four criteria:
At the Mayo Clinic, MGUS transformed into multiple myeloma or similar lymphoproliferative disorder at the rate of about 1-2% a year, or 17%, 34%, and 39% at 10, 20, and 25 years, respectively, of follow-up—among surviving patients…”
“Plasmacytoma refers to plasma cell tumor growing within soft tissue or within the axial skeleton…Solitary Plasma of the Bone (SPB) and extramedullary plasmacytomas are mostly treated with radiotherapy, but surgery is used in some cases of extramedullary plasmacytoma.
The diagnosis of plasmacytoma uses a diverse range of interdisciplinary techniques including serum protein electrophoresis, bone marrow biopsy, urine analysis for Bence Jones protein and complete blood count, plain film radiography, MRI and PET-CT.
Most cases of SPB progress to multiple myeloma within 2–4 years of diagnosis, but the overall median survival for SPB is 7–12 years. 30–50% of extramedullary plasmacytoma cases progress to multiple myeloma with a median time of 1.5–2.5 years. 15–45% of SPB and 50–65% of extramedullary plasmacytoma are disease free after 10 years.”